ArticleWorld journal of gastrointestinal surgery2025
Clinical significance of immune cell and biomarker changes in liver cancer.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary liver cancer (PLC) is characterized by high malignancy, rapid disease progression, and persistent high incidence and mortality rates, posing a significant public health challenge worldwide. Early diagnosis and assessment of PLC are of great significance for guiding clinical treatment and improving patient prognosis. Alpha fetoprotein (AFP) and gamma-glutamyl transpeptidase (GGT) are commonly utilized tumor markers for the clinical diagnosis of PLC. They are ideal indicators for the detection of metastasis and recurrence after LC surgery. Nevertheless, not all patients with PLC secrete large amounts of AFP and GGT, which affects the accuracy of evaluating PLC by monitoring these two tumor markers alone. Cluster of differentiation 3 and 161 double-positive natural killer T (CD3
aimTo probe the clinical significance of CD3
methodsThe PLC group comprised 30 patients diagnosed with PLC who were admitted to our hospital between July 2022 and December 2023, whereas the control group consisted of 30 healthy individuals undergoing routine physical examinations at our hospital. Peripheral blood samples were harvested from both cohorts of patients. The levels of CD4
resultsNo significant disparities were observed in the counts of white blood cells, neutrophils, and platelets, as well as the levels of blood urea nitrogen and serum creatinine between the two groups (
conclusionThe levels of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.